Unlock instant, AI-driven research and patent intelligence for your innovation.

Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof

A compound and hydrocarbon-based technology, applied in the field of polyphosphate nucleoside derivatives and pharmaceutical compositions containing them, can solve problems such as unqualified and unstable alkaline phosphatase

Inactive Publication Date: 2010-12-22
BAR ILAN UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The insulin-releasing effect of 2-MeS-ATP-α-B is glucose-dependent, suggesting that this compound may be a drug candidate for the treatment of type 2 diabetes; however, it was found to be unstable to alkaline phosphatase, which makes this compound useful as a drug is substandard

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof
  • Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof
  • Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0122] Example 1. β,γ-CH 2 -2MeS-adenosine-5'-triphosphate (2) synthesis

[0123] β,γ-CH was prepared by two methods as shown in Scheme 1 and described below 2 -2MeS-adenosine-5'-triphosphate (2):

[0124] Method A. Bis(tributylammonium)methylene diphosphonate was prepared as described above. In a flame-dried two-necked flask, 1,8-bis(dimethylamino)naphthalene (117mg, 0.57mmol, 1.5eq) was added to 2 ',3'-O-methoxymethylene-2-MeS-adenosine (5a) (130 mg, 0.37 mmol), and the reaction was stirred for 20 minutes until a clear solution was obtained. Add POCl at 0°C 3 (67 μl, 1.09 mmol, 3 eq). The solution was stirred at 0 °C for 3 hours. A 0.5M solution of bis(tributylammonium)methylene diphosphonate (386mg, 2.19mmol, 6eq) in anhydrous DMF (4.3ml) and tributylamine (360μl, 1.46mmol, 4eq) were added at 0°C , and the reaction mixture was stirred for 1.6 minutes. A 0.25M solution of ammonium acetate (10 ml) was added at room temperature and the reaction mixture was stirred for ...

Embodiment 2

[0126] Example 2. Adenosine-β,γ-CH 2 Synthesis, Isolation and Characterization of -5'-O-(1-Borane Triphosphate)(3)

[0127] Adenosine-β,γ-CH 2 -5'-O-(1-borane triphosphate) (3) synthesis

[0128] Bis(tributylammonium)methylene diphosphonate was prepared by mixing Bu 3 N (2 eq) was added to the free acid of methylene diphosphonic acid in EtOH and stirred for 2 hours, then the solvent was removed under reduced pressure to give a white solid. As described in Scheme 2, 2′,3′-O-methoxymethyleneadenosine 9 (100 mg, 0.32 mmol) was dissolved in trimethylphosphate in a flame-dried two-necked flask under nitrogen ester (2.5ml). At 0°C, 1,8-bis(dimethylamino)naphthalene (138mg, 0.65mmol, 2eq) was added and the reaction was stirred for 20 minutes until a clear solution was obtained. Add PCl at 0°C 3 (56 μl, 0.65 mmol, 2 eq), a white solid precipitated. The suspension was stirred at 0°C for 30 minutes. Then, a 1M solution of bis(tributylammonium)methylene diphosphonate (642 mg, 1.9...

Embodiment 32

[0135] Example 3.2MeS-adenosine-β,γ-CH 2 Synthesis, Isolation and Characterization of -5'-O-(1-Borane Triphosphate)(4)

[0136] 2MeS-adenosine-β,γ-CH 2 -5'-O-(1-borane triphosphate) (4) synthesis

[0137] In the same manner as described for product 3 in Example 2, product 4 was obtained from 5a in 28% overall yield after LC separation as shown in Scheme 2 below.

[0138] 2MeS-adenosine-β,γ-CH 2 -Isolation of 5'-O-(1-borane triphosphate) (4)

[0139] Separation of the 4 diastereomers was achieved using a semi-preparative reversed-phase Gemini 5u column (C-18110A, 250 x 10.00 mm, 5 microns) and isocratic elution: a solvent system I of 75:25 A:B was applied ( See Example 1), the flow rate is 5ml / min. Final separation of the two diastereomers was achieved using an analytical Gemini 5u column (C-18110A, 150 x 4.6 mm) and solvent system I (see Example 1): Gradient 82:18 to 74:26 A:B , lasted 20 minutes, the flow rate was 1ml / min. Fractions containing the same isomer [Rt = 9.7...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides non-hydrolyzable nucleoside polyphosphate derivatives, e.g., 2MeS-adenosine-beta, gamma-CH2-5'-O-(1-boranotriphosphate), 2MeS-adenosine-beta, gamma-CC12-5'-O-(1-boranotriphosphate), 2-MeS-adenosine-5'-dichloro methylene-diphosphate, 2-MeS-adenosine-5'-difluoromethylene- diphosphate and 2MeS-adenosine-5'-O-(1-boranodiphosphate), as well as pharmaceutical compositions thereof. These compounds are useful for prevention or treatment of diseases or disorders modulated by P2Y-receptors such as type 2 diabetes, and for pain control.

Description

field of invention [0001] The present invention relates to non-hydrolyzable nucleoside polyphosphate derivatives and pharmaceutical compositions containing them. The compounds are useful in the prevention or treatment of diseases or conditions modulated by P2Y receptors, and in pain management. Background of the invention [0002] The P2 receptor (P2R) superfamily consisting of ligand-gated ion channels (P2XR) and G protein-coupled receptors (P2YR) is primarily activated by the extracellular nucleosides ATP, ADP, UTP or UDP (Jacobson et al. 2002). In addition, P2 receptors are activated by several dinucleotide polyphosphates (dinucleotides) (WO 2003 / 0207825; Shaver et al., 2005). [0003] P2YRs are attractive drug targets because they are involved in the regulation of various functions in many tissues and organs under normal and pathophysiological conditions (Williams and Jarvis, 2000; Guile et al., 2001; Fischer, 1999), thus making P2YR agonists emerged as promising drug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H19/06C07H19/16A61K31/7076A61P3/10
CPCC07F9/65616C07F9/65746C07F9/65744C07H19/16C07H19/06A61P1/02A61P1/10A61P11/00A61P15/02A61P27/02A61P27/04A61P27/06A61P27/16A61P29/00A61P35/02A61P43/00A61P7/02A61P9/00A61P9/04A61P9/10A61P3/10
Inventor B·费希尔S·埃亚胡
Owner BAR ILAN UNIV